Latest Top Holdings of Ruiyuan Fund's Products Exposed: Fu Pengbo first opened a position in Torchlight Technology, and Zhao Feng bought back Wuhan Medicine.

On July 17th, the in-managed products of two star fund managers under Rayuan Fund disclosed their second quarter report for 2026, and their latest top ten heavy stocks also emerged. During the second quarter of 2026, the Hong Kong stock position of Rayuan Growth Value Hybrid Fund, managed by Fu Pengbo and Zhu Lin, has dropped to its lowest level in history. In terms of adjusting positions and changing stocks, the fund initiated a position in Juguang Technology for the first time, and significantly reduced its holdings in Zhong Jiuchuang and Dongshan Precision. Rayuan Balanced Value Three-Year Hold, managed by another star fund manager of Rayuan Fund, Zhao Feng, then bought back Yiming Biological after one year, and also increased its holdings in Zhongtong Express and China Resources Land.